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Summary
When deciding on adjuvant radiotherapy in breast cancer patients, the decision is made based on the type of surgery 
(radical or conserving) and pathological report. In case systemic treatment is given before surgery, initial pathological 
 report, which presents the backbone in decision making, is partly missing. Data from prospective randomized trials are 
lacking, and published retrospective data are inconsistent. Current guidelines are not clear for a large subset of patients. 
Also, guidelines and real-life data are often in discordance. This article aims to present literature data regarding the risk of 
locoregional relapse after neoadjuvant systemic treatment, the impact of radiotherapy on the risk of locoregional relapse, 
current clinical trial that is expected to give an answer in which subset of patients should adjuvant radiotherapy be per-
formed and published clinical practice data.
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RADIOTERAPIJA NAKON NEOADJUVANTNOG SUSTAVNOG LIJEČENJA RAKA DOJKE
Sažetak
Kod postavljanja indikacije za adjuvantno zračenje bolesnica s rakom dojke vodimo se vrstom kirurškog zahvata (ra-
dikalni ili poštedni) te patohistološkim nalazom. U slučaju da je sistemska terapija provedena prije kirurškog zahvata, ne-
dostaje dio patohistološkog nalaza koji je okosnica u donošenju odluke. Objavljenih prospektivnih randomiziranih studija 
nema a retrospektivni podaci su nekonzistentni. Trenutne smjernice nisu jasne za veliku podskupinu bolesnica. Osim toga 
smjernice i podaci iz kliničke prakse se često ne podudaraju. Cilj ovog rada je prikazati podatke iz literature po pitanju rizi-
ka nastanka lokoregionalnog relapsa nakon neoadjuvantnog sistemskog liječenja, učinak radioterapije na smanjenje rizika 
lokoregionalnog relapsa, kliničku studiju koja bi trebala dati odgovor kod koje skupine bolesnica bi bilo uputno provesti 
zračenje te objavljene podatke iz kliničke prakse.
KLJUČNE RIJEČI: zračenje raka dojke, neoadjuvantno sustavno liječenje raka dojke
INTRODUCTION
Adjuvant radiotherapy of breast cancer is un-
doubtedly effective treatment; it reduces the rate 
of local relapse, distant metastases, and improves 
survival. However, these effects can be limited in 
a certain subgroup of patients (1,2). Radiotherapy 
is also associated with specific side effects, the 
most dangerous being cardiac toxicity and devel-
opment of secondary cancers, and the most com-
mon being cosmetic ones (3,4). Indication for adju-
vant radiotherapy is based on the risk of local re-
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currence based on the type of surgical treatment 
(radical or breast-conserving) and complete patho-
logic analysis of untreated tumor and nodal tis-
sues. Considerable volumes of prospective and 
retrospective literature support the use of radio-
therapy in subgroups of patients. In general, adju-
vant radiotherapy is indicated in patients with 
positive axillary lymph nodes and in all patients 
after breast-conserving surgery, except in those 
older than 70 years with pT1N0 hormone positive 
tumours, and in patients with pT3-4 tumours after 
mastectomy.
Neoadjuvant systemic treatment (NAST) of 
breast cancer is not a new approach; it started in 
1970-es in patients with the locally advanced irre-
sectable disease. The therapy aimed to achieve re-
sectability. All those patients had a high risk of 
local recurrence, and all of them met the criteria 
for adjuvant radiotherapy (5). In the last 20 years, 
NAST is used in patients with small, initially re-
sectable tumors. Despite advances in diagnostics, 
one cannot be sure of the initial extent of the dis-
ease since the complete pathological analysis of 
untreated tumor is lacking. Therefore, it can be 
challenging to estimate the risk of local relapse 
and justify adjuvant radiotherapy. Data from pro-
spective randomized trials are still pending.
LITERATURE DATA
Impact of neoadjuvant chemotherapy  
on local control
Results of two meta-analyses show that breast 
cancer patients who were given neoadjuvant che-
motherapy have a higher risk of local relapse 
when compared to patients that received chemo-
therapy postoperatively.
Mauri et al. evaluated nine randomized trials 
that included 3946 patients with breast cancer, 
comparing neoadjuvant and adjuvant chemo-
therapy, additional surgery and/or radiation re-
gardless. Primary outcomes were death, disease 
progression, distant disease recurrence, and lo-
coregional disease recurrence. There was no sta-
tistically or clinically significant difference be-
tween the two therapy arms regarding death (RR= 
0.99), disease progression (RR= 0.99), or distant 
disease recurrence (RR= 0.94). Neoadjuvant ap-
proach to chemotherapy was statistically signifi-
cantly associated with increased risk of locore-
gional recurrence (RR= 1.22), compared with the 
same therapy given postoperatively. This was 
even more expressed in a group of patients who 
had a complete clinical response and, therefore, 
received just radiation therapy without surgery 
(RR= 1.53). Trials were performed between 1983 
and 1999. It is worth mentioning that taxanes were 
not given in any of the trials (6).
EBCTCG’s meta-analysiss published in 2018 
analyzed data from 4756 breast cancer patients in-
cluded in 10 randomized trials comparing neoad-
juvant (NAST) and adjuvant chemotherapy. Trials 
were performed between 1982 and 2003. In just 
one trial combination of anthracyclines and tax-
anes was used. Primary outcomes were tumor re-
sponse, the extent of local therapy, local and dis-
tant recurrence, breast cancer death, and overall 
mortality. Median follow up was nine years. Six-
tynine percent of women allocated to NAST 
groups had a complete or partial clinical response 
and were more likely to have breast conserving 
treatment than patients who were operated ini-
tially (65% vs 49%). No significant difference be-
tween NAST and adjuvant chemotherapy was 
found regarding distant recurrence (15- year risk 
38.2% for NAST vs 38% for adjuvant chemothera-
py), breast cancer mortality (34.4% vs 33.7%) or 
death from any cause (49.9% vs 41.2%). However, 
NAST was associated with more frequent local re-
currence than was adjuvant chemotherapy; 15- 
year local recurrence was 21.4% for NAST and 
15.9% for adjuvant chemotherapy. The local recur-
rence data includes both the trials with surgery 
and the trials in which operation could be omitted 
depending on the response to NAST (7).
The question is, would these higher rates of 
local recurrence in patients receiving NAST even-
tually have an impact on distant recurrence and 
death of breast cancer (in case of longer follow 
up). Perhaps we should be more prone to radia-
tion therapy in patients receiving NAST bearing 
in mind worse local control it offers according to 
available data.
Predictors of locoregional recurrence
Following the trend towards least invasive 
treatment, it is necessary to define the group of pa-
tients with low risk of locoregional recurrence (LRR) 
in whom radiotherapy could be safely  omitted.
In the combined analysis of NSABP B 18 and 
27 authors defined predictors of (LRR) in patients 
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given NAST. The analysis included 3088 patients 
with operable palpable breast cancer cT1-3N0-
1M0, diagnosed by FNA or core needle biopsy. 
The axillary staging was performed with palpa-
tion only. Patients in NSABP B18 received 4 cycles 
of AC (doxorubicin + cyclophosphamide) pre or 
postoperatively and patients older than 50 were 
also given tamoxifen for 5 years, starting after che-
motherapy. In NSABP B 27 patients received 4 
cycles of neoadjuvant AC, either alone or followed 
by 4 cycles of neoadjuvant docetaxel or 4 cycles of 
docetaxel postoperatively. All patients received 
tamoxifen for 5 years, starting on the first day of 
chemotherapy, regardless of their hormone recep-
tor status. In both studies, patients undergoing 
lumpectomy received breast radiotherapy alone. 
In case they had a mastectomy, no radiotherapy 
was given, which was in concordance with guide-
lines valid at that time. This omission of radiother-
apy provides us with the natural course of the dis-
ease after NAST in context of local recurrence and 
helps to identify its independent predictors.
After 10 year-follow up the cumulative inci-
dence of LRR for mastectomy patients was 12.3% 
(8.9% local; 3.4% regional). Independent predic-
tors were clinical tumor size (> 5 cm), clinical nod-
al status, and pathologic nodal status/breast tu-
mor response. Regional nodal recurrence rates 
were low in clinically node-negative patients, ir-
respective of tumour size (2.3% to 4.3% for cT < 5 
cm and 2.3% to 6.2% for cT > 5 cm). In clinical 
node-positive (cN+) patients that remained posi-
tive after NAST (ypN+), nodal recurrence rates 
were 4.8%- 6.4%. In 32 patients with clinically pos-
itive lymph nodes that became pathologically 
negative, not a single case of LRR was noticed.
Cumulative incidence of LRR for patients 
treated with lumpectomy plus radiotherapy was 
10.3% (8.1% local, 2.2% regional). Independent 
predictors of LRR in lumpectomy group were age 
<50 years, clinical nodal status and pathologic 
nodal status/breast tumor response. Regional 
nodal recurrence rates were low for patients with 
clinically negative lymph nodes (0.5% to 2.3%) 
and for those with cN+ ypN- (0% to 2.4%). In cN+ 
patients who remained positive after NAST rates 
of regional recurrence were higher: 7.5% to 8.7%. 
Rates of LRR were generally higher for patients 
with at least four positive nodes compared to 
those with one to three positive nodes.
These results demonstrate that pathologic re-
sponse in the breast and pathologic axillary nodal 
status has a significant impact on LRR. They also 
suggest that the impact of age, clinical tumor size 
and clinical nodal status on LRR are low in case 
patients achieve a pathologic complete response 
(pCR) and in a case the breast tumor with patho-
logically negative axillary nodes. Therefore, sub-
groups of patients with low risk of LRR that might 
be spared of radiotherapy and its side effects are 
derived (8).
However, a pooled analysis on 3481 patients 
from the Gepar-trials (Trio, Quattro and Quinto) 
gives somewhat different results. It includes pa-
tients with operable and non-operable breast can-
cer for which information on the use of radiother-
apy (RT) was available. In these trials not only 
chemotherapy, but also targeted therapies were 
tested in neoadjuvant setting (trastuzumab in Ge-
parQuattro, trastuzumab, lapatinib, bevacizumab 
and everolimus in GeparQuinto). Locoregional re-
currence was defined as a recurrence in the breast, 
at the chest wall or in the regional lymph nodes. 
After a median follow-up of 55.9 months, the 
overall risk of LRR was 8.3%. Patients who under-
went radiotherapy had a significant benefit in 
terms of 5-year LRR-free survival (LRFS, 90% vs. 
81.5% without radiotherapy, p < 0.001) and 5-year 
disease-free survival (DFS, 75.4% vs. 67.4%, p < 
0.001). In patients with pathologic complete re-
sponse, the 5-year LRFS was 95.7%% with radio-
therapy vs. 86.6% without radiotherapy (HR 3.32; 
p = 0.051) and 5-year DFS was 86.9% and 56.1% 
respectively (HR 3.52; p < 0.001). The absolute ad-
vantage of radiotherapy regarding both LRFS and 
DFS was highest among patients with clinically 
positive lymph nodes.
Multivariate analysis confirmed radiothera-
py as an independent prognostic factor for LRFS 
(HR 0.54; p = 0.004) and DFS (HR 0.69; p = 0.016). 
In conclusion, patients who were not irradiated 
after neoadjuvant systemic treatment for breast 
cancer had a significantly worse outcome, even if 
they achieved a pCR (9,10). Contrary to NSABP 
B18 and 27 results, according to these data, the 
pathological complete response should not be the 
reason for the omission of radiotherapy.
Current clinical trial
NSABP B-51/RTOG 1304 (NRG 9353) trial is 
expected to clarify whether cT1-3N1M0 breast 
cancer patients with the complete pathologic re-
sponse in lymph nodes after NAST should receive 
Lib Oncol. 2019;47(1):17–22
20
regional nodal radiotherapy. Metastases in lymph 
nodes should be confirmed by FNA or core-nee-
dle biopsy. ER/PR and HER-2neu status before 
NAST is required. After NAST (with antiHER2 
therapy for HER2 positive patients) definitive sur-
gery with histological documentation of negative 
axillary nodes, either by axillary dissection or sen-
tinel lymph node biopsy (SLNB) +/- axillary resec-
tion will take place. The minimal number of exam-
ined sentinel lymph nodes is three. Patients will 
be stratified based on the type of surgery (mastec-
tomy vs. lumpectomy), ER status, HER2 status and 
pCR in the breast (yes vs. no). Upon randomiza-
tion, patients in one group will not receive region-
al nodal radiotherapy; in case of the breast con-
serving surgery only breast radiotherapy will be 
performed, and in case of mastectomy, the patient 
will not be irradiated at all. In another group, pa-
tients will receive regional nodal radiotherapy, 
with breast or chest wall (depending on the type 
of surgery) included in the target volume. Region-
al nodes that are to be irradiated involve undis-
sected axilla, internal mammary nodes in the first 
three intercostal spaces and ipsilateral supracla-
vicular fossa. The outcome is breast cancer recur-
rence-free interval rate, including local, regional 
and distant recurrences and deaths resulting from 
breast cancer. Secondary aims are also second pri-
mary cancer or DCIS occurrence, and comparison 
of radiotherapy effect on cosmetics in reconstruct-
ed mastectomy patients. Correlative science ex-
amines radiotherapy effect by tumor subtype, mo-
lecular outcome predictors for residual disease 
patients, and predictors for the degree of reduc-
tion in locoregional recurrence.
Besides being the first randomized radiother-
apy trial in this indication, this trial is also impor-
tant for taking into consideration tumor biology 
(10, 11).
CLINICAL PRACTICE
In clinical practice disagreements in both in-
dications for radiotherapy and target volume defi-
nitions are being observed. Current guidelines, 
their occasional understatement regardless, are 
not always followed.
ACOSOGZ1071 prospective trial included 
685 breast cancer patients staged T0-4, N1-2 M0 
that underwent neoadjuvant chemotherapy. 
Lymph node metastases were confirmed with 
FNA or core biopsy. The study was designed to 
evaluate the false-negative rate of sentinel lymph 
node biopsy (SLNB) after neoadjuvant chemo-
therapy. Therefore, upon chemotherapy comple-
tion, mastectomy, with or without immediate re-
construction, or breast-conserving surgery (BCS) 
was performed. All patients had SLNB followed 
by axillary dissection. Radiation therapy decisions 
were at the discretion of the physicians.
Of the 685 patients, 401 (58.5%) remained 
node-positive following chemotherapy. In this 
group of patients, mastectomy was performed in 
148 (36.9%), mastectomy with immediate recon-
struction in 107 (26.7%), and breast-conserving 
surgery in 146 (36.4%). Of the 284 node-negative 
patients, mastectomy was performed in 84 (29.6%), 
mastectomy with immediate reconstruction in 69 
(24.3%) and BCS in 131 (46.1%).
Radiotherapy was more frequently used in 
patients undergoing mastectomy without recon-
struction; 87.9%, vs. 76.1% in patients undergoing 
mastectomy with reconstruction (p= 0.002). In pa-
tients that remained node-positive after NAST, 
radiotherapy was used in 89.9% after mastectomy 
and in 82.2% of patients after mastectomy with re-
construction. This difference was not statistically 
significant (p= 0.077). Final pathologic T- stage, 
and N-stage did not differ between these two 
groups. In those patients converting to node-neg-
ative after NAST, radiotherapy was employed in 
84.5% of the mastectomy patients compared to 
66.7% of those that underwent mastectomy with 
reconstruction (p< 0.001).
Clinical target volumes differed widely. In-
ternal mammary radiation use ranged from 7.8% 
to 11.2%, and rates of supraclavicular radiation 
ranged from 46.6% to 52.2%. Neither differed be-
tween surgical approaches, pathological tumor 
stage, or nodal response. Supraclavicular radia-
tion was omitted in 47.3% of patients with the re-
sidual node-positive disease after NAST. Axillary 
radiotherapy was used more frequently in those 
patients remaining node-positive after NAST (p= 
0.002), and in those with residual disease in the 
breast (p=0.025). Axillary radiation was used less 
frequently in patients undergoing breast-conserv-
ing surgery. It is to be noticed that 22% of patients 
who converted to pathologic node-negative dis-
ease and underwent completion axillary lymph 
node dissection received axillary radiation (12).
The impact of pathological complete re-
sponse (pCR) on disease control has been con-
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firmed in this trial. Patients with pCR had a sig-
nificantly better locoregional recurrence (LRR) 
free survival (p= 0.003), distant relapse (DR) free 
survival (p= 0.002), breast cancer-specific survival 
(p= 0.0007) and overall survival (p= 0.001) com-
pared to patients with residual disease. The pa-
tient who did not receive adjuvant radiotherapy 
had a two-fold higher risk of LRR. That difference, 
although not statistically significant, was also ob-
served in pN0 patients (p= 0.15). Radiotherapy 
was associated with a trend toward improved lo-
cal-regional control in both pathological node-
positive and pathological node-negative patients. 
There was no difference regarding the use of ra-
diotherapy in terms of DR, breast cancer-specific 
and overall survival (13).
National Cancer Database (NCDB) Analysis 
explored the impact of post-mastectomy and re-
gional nodal irradiation (RNI) after neoadjuvant 
chemotherapy (NAC) for clinically lymph node-
positive breast cancer patients. Patients with cT1-
3N1M0 breast cancer treated with NAS were di-
vided into four cohorts depending on the surgical 
procedure (mastectomy- Mast vs. breast-conserv-
ing surgery- BCS) and post-chemotherapy patho-
logic nodal status (ypN0 vs. ypN+). Therefore, 
among 15 315 patients treated in the period be-
tween 2003 and 2011, 3040 patients were classified 
as Mast- ypN0, 7243 as Mast- ypN+, 2070 as BCS- 
ypN0 and 2962 as BCS- ypN+. Radiotherapy field 
design data included breast- only, chest wall- only, 
breast plus RNI and chest wall plus RNI. The pri-
mary endpoint for Mast patients was overall sur-
vival (OS) from diagnosis with post-mastectomy 
radiotherapy (PMRT) - with or without regional 
nodal irradiation (RNI) - versus no PMRT. Sec-
ondary endpoint for PMRT patients was OS by 
RNI. For BCS patients, the primary endpoint was 
OS with breast radiotherapy alone versus breast 
radiotherapy plus RNI. BCS patients who did not 
undergo radiotherapy were excluded.
On univariate analysis, post-mastectomy ra-
diotherapy was associated with improved OS in 
both Mast- ypN0 and Mast- ypN+ patients (p= 
0.019 and p< 0.001, respectively). PMRT remained 
independently associated with improved overall 
survival in both subgroups of patients on multi-
variate analysis adjusted for factors including age, 
comorbidity score, cT stage, in-breast complete 
pathologic response, axillary surgery, ypN stage, 
estrogen receptor status and hormone therapy. 
Post-mastectomy radiotherapy improved overall 
survival in each pathologic nodal subgroup 
(ypN0, ypN1, and ypN2-3, all p values <0.05). In 
patients undergoing breast-conserving treatment 
no differences in overall survival were observed 
when adding regional nodal irradiation to breast 
radiotherapy in both BCS- yPN0 and BCS- ypN+ 
subgroups of patients. (14).
CURRENT GUIDELINES
According to NCCN guidelines, adjuvant ra-
diotherapy should be based on maximal disease 
stage from pre-chemotherapy tumor characteris-
tics at diagnosis and post-chemotherapy patho-
logic results. In case the patient underwent 
lumpectomy, adjuvant radiation is indicated to 
the whole breast, with or without a boost to the 
tumor bed. For clinical N1, ypN0, radiation to the 
whole breast + infraclavicular region, supraclavic-
ular area, internal mammary nodes and any part 
of the axillary bed at risk should be strongly con-
sidered. For any positive axillary nodes after che-
motherapy, radiation therapy as indicated to the 
whole breast + infraclavicular region, supraclavic-
ular area, internal mammary nodes and any part 
of the axillary bed at risk.
After the mastectomy, for clinical N1, ypN0, 
radiation to the chest wall + infraclavicular region, 
supraclavicular area, internal mammary nodes 
and any part of the axillary bed at risk should be 
strongly considered. For any positive axillary 
nodes after chemotherapy, radiation therapy as 
indicated to the chest wall + infraclavicular region, 
supraclavicular area, internal mammary nodes 
and any part of the axillary bed at risk (15).
American society of clinical oncology, Ameri-
can society for radiation oncology and Society of 
surgical oncology-focused guideline update pub-
lished in 2016, suggests that patients with clinical 
stage I or II who have received NAST prior to mas-
tectomy should also receive postmastectomy radio-
therapy in case of axillary nodal involvement that 
persists after NAST (less than a complete patho-
logical response), although there are no data from 
randomised trials showing the effect of such treat-
ment on long-term breast cancer mortality rates.
In case of a complete pathological response 
in this subgroup of patients, as well as in patients 
who have clinically negative nodes and receive 
NAST, the panel believes that there is currently in-
sufficient evidence to recommend whether post-
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mastectomy radiation should be administered or 
routinely omitted. Those patients should enter 
into clinical trials (5).
CONCLUSION
Patients that undergo neoadjuvant systemic 
treatment present a heterogeneous group. Since 
initial pathologic report of untreated tumor, on 
which we base the indication, is incomplete and 
randomised trial data are pending, the optimal ap-
proach for this group of patients is still debatable. 
According to retrospective data, indication for ad-
juvant radiotherapy should be based on initial clin-
ical-stage, type of surgical procedure and response 
of the tumor to neoadjuvant systemic treatment. In 
the case of any uncertainties, patient’s age, comor-
bidities, tumor biology, and further systemic treat-
ment option should be taken into consideration.
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